100 Chapter 4 27. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. Journal of neurology, neurosurgery, and psychiatry. 1992;55(10):967-72. 28. Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. NeuroImage. 2011;56(3):907-22. 29. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage. 2002;17(1):479-89. 30. Gangishetti U, Christina Howell J, Perrin RJ, Louneva N, Watts KD, Kollhoff A, et al. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease. Alzheimers Res Ther. 2018;10(1):98. 31. Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA neurology. 2019;76(7):791-9. 32. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology. 2018;14(10):577-89. 33. Yang Z, Wang KKW. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364-74. 34. Zetterberg H. Review: Tau in biofluids - relation to pathology, imaging and clinical features. Neuropathology and applied neurobiology. 2017;43(3):194-9. 35. Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. EMBO Mol Med. 2019;11(12):e11170. 36. Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurology. 2013;12(2):207-16. 37. McDade E, Wang G, Benzinger TLS, Buckles VD, Fagan AM, Gordon BA, et al. LONGITUDINAL BIOMARKER CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE FROM THE DIAN STUDY. Alzheimer’s & Dementia. 2017;13(7, Supplement):P879-P80. 38. Lleó A, Alcolea D, Martinez-Lage P, Scheltens P, Parnetti L, Poirier J, et al. LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER’S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. Alzheimer’s & Dementia. 2017;13(7, Supplement):P924. 39. Clerx L, van Rossum IA, Burns L, Knol DL, Scheltens P, Verhey F, et al. Measurements of medial temporal lobe atrophy for prediction of Alzheimer’s disease in subjects with mild cognitive impairment. Neurobiology of aging. 2013;34(8):2003-13. 40. Falgàs N, Sánchez-Valle R, Bargalló N, Balasa M, Fernández-Villullas G, Bosch B, et al. Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer’s disease patients: A comparison between visual and quantitative assessment. Neuroimage Clin. 2019;23:101927.